Apixaban Clinical Trial to Prevent Blood Clots in Lung Cancer Patients

Strategic Insights -

A Phase 3 clinical trial has been initiated by the University of Birmingham to investigate the efficacy of apixaban in preventing blood clots in lung cancer patients undergoing systemic anticancer treatment. The trial aims to enroll a sample of 1456 participants from the USA and will be led by principal investigator Michael Newnham, MBChB, MSc, MRCP, PhD. The study will involve a duration of 6 months, during which participants will receive either apixaban or a placebo, in addition to their standard lung cancer treatment. The trial's primary objective is to determine whether apixaban can reduce the incidence of blood clots in these patients.

Key Takeaways:

  • The clinical trial, ID: NCT07160686, is a Phase 3 study aiming to investigate the efficacy of apixaban in preventing blood clots in lung cancer patients.
  • The study will enroll a sample of 1456 participants from the USA and will be conducted for a duration of 6 months.
  • The primary objective of the trial is to determine whether apixaban can reduce the incidence of blood clots in patients with lung cancer undergoing systemic anticancer treatment.
  • Participants will receive either apixaban or a placebo, in addition to their standard lung cancer treatment, and will be required to complete a participant diary and quality of life and health resource use questionnaires.
  • Female participants of childbearing potential will be required to use adequate contraception during the trial and for at least 2 days after trial treatment has finished.

Statistics:

  • Sample size: 1456 participants
  • Duration of the study: 6 months
  • Number of participants to be enrolled from the USA: 1456
  • Type of treatment: Apixaban or placebo, taken orally twice a day
  • Age and gender requirements not specified in the original text
  • Total duration of follow-up for participants: expected to be 10-12 months

Sources:

  • ClinicalTrials.gov: ID: NCT07160686